IV Ascorbic Acid Synergy with Modulated Electro-Hyperthermia; a study demonstrating that there is a way to elevate IV Ascorbic Acid. IVAA can have improved efficacy in a cancer treatment scenario when combined with modulated Electro-Hyperthermia, administered with the Oncotherm EHY2000 Plus device. This is the exact device that Integrated Health Clinic pioneered in North America and that we continue to use for integrative cancer care.
The safety and pharmacokinetics of high dose intravenous ascorbic acid synergy with modulated electrohyperthermia in Chinese patients with stage III-IV non-small cell lung cancer
Ascorbic acid (AA) infusion and modulated electrohyperthermia (mEHT) are widely used by integrative cancer practitioners for many years. However, there are no safety and pharmacokinetics data in Chinese cancer patients. We carried out a clinical trial to evaluate the safety and pharmacokinetics of those methods in patients with stage III-IV non-small cell lung cancer (NSCLC). Blood ascorbic acid in the fasting state was obtained from 35 NSCLC patients; selecting from them 15 patients with stage III-IV entered the phase I study. They were randomized allocated into 3 groups, and received doses 1.0, 1.2, 1.5 g/kg AA infusions. Participants in the ﬁrst group re-ceived intravenous AA (IVAA) when mEHT was ﬁnished, in the second group IVAA was administered si-multaneously with mEHT and in the third group IVAA was applied ﬁrst, and followed with mEHT. Pharmacokinetic proﬁles were obtained when they received solely IVAA and when IVAA in combination with mEHT. The process was applied 3 times a week (every other day, weekend days oﬀ) for 4 weeks. We found that fasting plasma AA levels were signiﬁcantly correlated with stage of the disease. Peak concentration of AA was signiﬁcantly higher in the simultaneous treatments than in other combinations with mEHT or in solely IVAA-managed groups. IVAA synergy with simultaneous mEHT is safe and the concomitant application significantly increases the plasma AA level for NSCLC patients.
Junwen Ou, Xinyu Zhu, Yimin Lu, Changlin Zhao, Hongyu Zhang, Xiaopu Wang, Xiaoshi Gui, Junhua Wang, Xinting Zhang, Tao Zhang, Cliﬀord L.K. Pang. The safety and pharmacokinetics of high dose intravenous ascorbic acid synergy with modulated electrohyperthermia in Chinese patients with stage III-IV non-small cell lung cancer. European Journal of Pharmaceutical Sciences 109 (2017) 412-418
Cancer Center, Cliﬀord Hospital, Guangzhou University of Chinese Medicine, No.3. Hongfu Road, Panyu District, Guangzhou 511495, PR China
Basic Medicine, Guangzhou University of Chinese Medicine, No.232 Waihuan Dong Road, Guangzhou Higher Education Mega Center Town, Panyu, Guangzhou 510006, PR China
Hyperthermia Center, Cliﬀord Hospital, Guangzhou University of Chinese Medicine, No.3 Hongfu Road, Panyu District, Guangzhou 511495, PR China
To view the publication, Click Here: Download
For more information on Modulated-Electro-Hyperthermia, Click Here.
For more information on IV Ascorbic Acid, Click Here.
Or contact us at the IHC Cancer Care Centre receptionist via email at email@example.com or phone at 604-888-8325, option #1.
Gurdev Parmar, BSc., ND